# Cellectar Biosciences

Source: https://onco.cc/companies/cellectar/  
OnCo record `cellectar` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cellectar is a New Jersey radiopharmaceutical company whose iodine-131 phospholipid drug conjugate iopofosine targets the lipid rafts of cancer cells, with a pivotal trial (CLOVER-WaM) in relapsed Waldenström macroglobulinaemia.

## Summary

Cellectar Biosciences, based in Florham Park, New Jersey and listed on Nasdaq, develops phospholipid drug conjugates that exploit the lipid rafts abundant on cancer cell membranes to deliver radioisotopes or cytotoxics. Its lead, iopofosine I-131 (CLR 131), delivers iodine-131 and reported its pivotal CLOVER-WaM results in relapsed Waldenström macroglobulinaemia in 2024; earlier studies covered multiple myeloma and paediatric high-grade glioma. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Cellectar Biosciences, Inc.; Cellectar
- Tags: ctgov-sponsor
- HQ: Florham Park, NJ
- Type: radiopharma
- Website: https://www.cellectar.com

## Sources

- Official website: https://www.cellectar.com
- ClinicalTrials.gov: trials led by Cellectar Biosciences: https://clinicaltrials.gov/search?lead=Cellectar%20Biosciences

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)

---
JSON: https://onco.cc/api/v1/entities/cellectar.json